STAT3 and non-small cell lung carcinoma: In parallel, we conducted a phase II clinical trial evaluating the combination of danvatirsen and checkpoint blockade in cancers that have previously demonstrated efficacy with STAT3 blockade: PDAC, NSCLC and CRC.6, 9